Breaking News Instant updates and real-time market news.

ALXN

Alexion

$98.41

-1.53 (-1.53%)

15:25
10/20/19
10/20
15:25
10/20/19
15:25

Alexion ULTOMIRIS receives FDA approval for Atypical Hemolytic Uremic Syndrome

Alexion Pharmaceuticals announced that the U.S. Food and Drug Administration approved ULTOMIRIS for the treatment of atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy for adult and pediatric patients. This is the first pediatric approval for ULTOMIRIS. Atypical HUS is an ultra-rare disease that can cause progressive injury to vital organs, primarily the kidneys, via damage to the walls of blood vessels and blood clots. The FDA approval is based on data from two global, single-arm open-label studies of ULTOMIRIS - one in adults and one in children, referred to as pediatrics in the study - with aHUS. The pediatric study is ongoing and a total of 14 out of 16 children were enrolled and included in the interim analysis. Efficacy evaluation of Complete TMA Response was defined by hematologic normalization parameters and improved kidney function. In the initial 26-week treatment periods, 54% of adults and 71% of children demonstrated Complete TMA Response. Treatment with ULTOMIRIS resulted in reduced thrombocytopenia in 84% of adults and 93% of children, reduced hemolysis in 77% of adults and 86% of children, and improved kidney function in 59% of adults and 79% of children. The most frequently observed adverse reactions reported in these studies were upper respiratory tract infection, diarrhea, nausea, vomiting, headache, hypertension and pyrexia. Serious meningococcal infections have occurred in patients treated with ULTOMIRIS. To minimize the risk for patients, specific risk-mitigation plans, including a REMS, have been established for ULTOMIRIS. Regulatory filings for marketing authorizations of ULTOMIRIS for the treatment of aHUS in the European Union and Japan are under review with regulators.

  • 23

    Oct

  • 04

    Nov

  • 07

    Dec

ALXN Alexion
$98.41

-1.53 (-1.53%)

10/04/19
GUGG
10/04/19
NO CHANGE
GUGG
Guggenheim positively biased on Biotech heading into earnings
Guggenheim analysts Whitney Ijem, Etzer Darout, Yatin Suneja and Michael Schmidt offered a preview for their joint Biotech coverage ahead of the group's earnings reporting season. Biotech stocks continued their downward trend in the quarter amid negative market sentiment and the analysts think the bar for companies to raise 2019 guidance again may be a bit higher following increases in FY19 consensus estimates on the heels of strong Q2 earnings results. However, they are postively biased on the group and have confidence in FY19 guidance and estimates, the analysts said. They see Alexion (ALXN), Biogen (BIIB), Genmab (GMAB), GW Pharmaceuticals (GWPH), Incyte (INCY), Neurocrine (NBIX), Regeneron (REGN) and Seattle Genetics (SGEN) as well positioned relative to expectations, Ijem, Darout, Suneja and Schmidt tell investors.
10/16/19
PIPR
10/16/19
NO CHANGE
Target $180
PIPR
Overweight
Piper likes Alexion acquisition of Achillion, remains buyer of shares
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Alexion Pharmaceuticals (ALXN) with a $180 price target after this morning's announced acquisition of Achillion Pharmaceuticals (ACHN). The deal brings in danicopan, an oral Factor D inhibitor, as combination therapy with Soliris for the treatment of paroxysmal nocturnal hemoglobinuria and monotherapy for C3 glomerulopathy, and ACH-5228, a second generation oral Factor D inhibitor, expected to enter the clinic early next year, Raymond tells investors in a research note. The analyst likes the deal. Achillion has already shown proof of concept in PNH and strategically the company adds to the diversification of Alexion's pipeline, says Raymond. The analyst remains a buyer of Alexion shares.
10/17/19
BOFA
10/17/19
INITIATION
Target $130
BOFA
Buy
Alexion reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Geoff Meacham reinstated coverage of Alexion Pharmaceuticals with a Buy rating and $130 price target. "Noise" around complement competition has overshadowed Alexion's "strong" fundamentals, driven by its Soliris/Ultomiris franchise, Meacham tells investors in a research note. The analyst likes the stock's risk/reward profile given the company's "differentiated" growth and "discounted" valuation.
10/18/19
LEER
10/18/19
DOWNGRADE
Target $6.3
LEER
Market Perform
Achillion acquisition by Alexion 'makes logical sense,' says SVB Leerink
SVB Leerink analyst Joseph Schwartz downgraded Achillion (ACHN) to Market Perform from Outperform with a price target of $6.30, up from $5. In a research note to investors, Schwartz says he thinks Alexion's (ALXN) proposed acquisition of Achillion makes logical sense as it brings highly complementary assets that can deliver a broader market opportunity together at a time "when the complement space could get more competitive." The analyst thinks the deal will close without any competing bids.

TODAY'S FREE FLY STORIES

GOOG

Alphabet

$1,298.76

-10.6 (-0.81%)

, GOOGL

Alphabet Class A

$1,297.98

-10 (-0.76%)

17:05
11/11/19
11/11
17:05
11/11/19
17:05
Periodicals
State AGs gather in Colorado to go over Google antitrust probe, Reuters says »

State attorneys general…

GOOG

Alphabet

$1,298.76

-10.6 (-0.81%)

GOOGL

Alphabet Class A

$1,297.98

-10 (-0.76%)

FB

Facebook

$189.57

-1.29 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNV

Franco-Nevada

$95.70

0.09 (0.09%)

17:03
11/11/19
11/11
17:03
11/11/19
17:03
Hot Stocks
Franco-Nevada reports 133,219 Gold Equivalent Ounces sold in Q3 »

"Franco-Nevada's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

FNV

Franco-Nevada

$95.70

0.09 (0.09%)

17:02
11/11/19
11/11
17:02
11/11/19
17:02
Earnings
Franco-Nevada reports Q3 EPS 54c, may not compare to consensus 27c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

ENR

Energizer

$43.11

-0.265 (-0.61%)

16:55
11/11/19
11/11
16:55
11/11/19
16:55
Hot Stocks
Energizer appoints new CFO, Chief Legal Officer, and Chief Accounting Officer »

Energizer Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 21

    Nov

LYV

Live Nation

$64.47

1.31 (2.07%)

16:52
11/11/19
11/11
16:52
11/11/19
16:52
Upgrade
Live Nation rating change  »

Live Nation upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BUD

AB InBev

$78.70

0.22 (0.28%)

, BREW

Craft Brew

$7.33

0.06 (0.83%)

16:51
11/11/19
11/11
16:51
11/11/19
16:51
Hot Stocks
Anheuser-Busch to buy remaining Craft Brew Alliance stake for $16.50 per share »

Today, Craft Brew…

BUD

AB InBev

$78.70

0.22 (0.28%)

BREW

Craft Brew

$7.33

0.06 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 13

    Nov

  • 27

    Feb

CHAP

Chaparral Energy

$0.90

0.089 (10.99%)

16:47
11/11/19
11/11
16:47
11/11/19
16:47
Earnings
Chaparral Energy reports Q3 EPS ($2.86), consensus 2c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

16:43
11/11/19
11/11
16:43
11/11/19
16:43
Hot Stocks
DXC Technology says will pursue strategic alternatives for adjacent business »

In Q2 presentation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

DXC

DXC Technology

$29.39

-0.69 (-2.29%)

16:41
11/11/19
11/11
16:41
11/11/19
16:41
Earnings
DXC Technology cuts FY20 EPS view to $5.25-$5.75 from $7.00-$7.75 »

Consensus $7.17. Cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

LONE

Lonestar Resources

$2.88

0.08 (2.86%)

16:35
11/11/19
11/11
16:35
11/11/19
16:35
Hot Stocks
Lonestar sees Q4 production 17,200-17,600 BOE/d »

Lonestar has issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NFE

New Fortress Energy

$15.86

-0.88 (-5.26%)

16:34
11/11/19
11/11
16:34
11/11/19
16:34
Earnings
New Fortress Energy reports Q3 EPS (30c), consensus (16c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 04

    Dec

TME

Tencent Music

$14.35

0.36 (2.57%)

16:34
11/11/19
11/11
16:34
11/11/19
16:34
Hot Stocks
Tencent Music reports Q3 online music Mobile MAUs up 0.9% »

Reports Q3: Mobile MAU up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

LONE

Lonestar Resources

$2.88

0.08 (2.86%)

16:33
11/11/19
11/11
16:33
11/11/19
16:33
Earnings
Lonestar has issued production guidance of 17,200 to 17,600 BOE/d for 4Q19. Prod »

Lonestar has issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

FEDU

Four Seasons Education

$2.08

0.09 (4.52%)

16:33
11/11/19
11/11
16:33
11/11/19
16:33
Hot Stocks
Four Seasons Education appoints Yi Zuo CEO »

Four Seasons Education…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LONE

Lonestar Resources

$2.88

0.08 (2.86%)

16:32
11/11/19
11/11
16:32
11/11/19
16:32
Earnings
Lonestar reports Q3 EPS 33c, may not compare to consensus (4c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

TME

Tencent Music

$14.35

0.36 (2.57%)

16:32
11/11/19
11/11
16:32
11/11/19
16:32
Hot Stocks
Tencent Music reports Q3 online music payers up 42.2% at 35.4M »

CEO Cussion Pang says:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

TME

Tencent Music

$14.35

0.36 (2.57%)

16:31
11/11/19
11/11
16:31
11/11/19
16:31
Earnings
Tencent Music reports Q3 EPS 10c, consensus 9c »

Reports Q3 revenue $910M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

KKR

KKR

$29.27

0.14 (0.48%)

, WBA

Walgreens Boots Alliance

$62.26

3.06 (5.17%)

16:31
11/11/19
11/11
16:31
11/11/19
16:31
On The Fly
Fly Intel: Wall Street's top stories for Monday »

Stocks were generally…

KKR

KKR

$29.27

0.14 (0.48%)

WBA

Walgreens Boots Alliance

$62.26

3.06 (5.17%)

EVR

Evercore Partners

$77.16

-1.14 (-1.46%)

BABA

Alibaba

$186.71

-0.4 (-0.21%)

LUV

Southwest

$58.27

0.1 (0.17%)

BA

Boeing

$366.97

16.32 (4.65%)

AAL

American Airlines

$30.58

-0.19 (-0.62%)

OTEX

OpenText

$42.54

0.99 (2.38%)

CARB

Carbonite

$22.93

4.54 (24.69%)

WE

We Company

$0.00

(0.00%)

TMUS

T-Mobile

$79.64

-1.28 (-1.58%)

S

Sprint

$5.91

-0.2 (-3.27%)

GOOG

Alphabet

$1,298.89

-10.47 (-0.80%)

GOOGL

Alphabet Class A

$1,298.21

-9.77 (-0.75%)

AAPL

Apple

$262.16

1.96 (0.75%)

AGEN

Agenus

$3.90

0.325 (9.10%)

URGN

UroGen Pharma

$24.16

0.59 (2.50%)

PLUG

Plug Power

$2.93

0.205 (7.54%)

MYOK

MyoKardia

$55.48

-4.51 (-7.52%)

SGMS

Scientific Games

$29.85

-1.74 (-5.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

  • 11

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 18

    Nov

  • 19

    Nov

  • 22

    Nov

  • 09

    Dec

  • 12

    Dec

  • 23

    Jan

BEN

Franklin Resources

$27.95

-0.33 (-1.17%)

16:31
11/11/19
11/11
16:31
11/11/19
16:31
Hot Stocks
Franklin Resources reports preliminary AUM $693.1B as of October 31 »

Compared to $692.6B at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APYX

Apyx Medical

$7.23

0.25 (3.58%)

16:30
11/11/19
11/11
16:30
11/11/19
16:30
Earnings
Apyx Medical raises FY19 revenue view to $27.4M-$27.9M from $26.5M-$27.5M »

Consensus $26.97M. Sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

  • 12

    Nov

RETA

Reata Pharmaceuticals

$213.50

1.46 (0.69%)

16:30
11/11/19
11/11
16:30
11/11/19
16:30
Hot Stocks
Breaking Hot Stocks news story on Reata Pharmaceuticals »

Reata Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

16:30
11/11/19
11/11
16:30
11/11/19
16:30
Options
Preliminary option volume of 14.8M today »

Preliminary option volume…

APYX

Apyx Medical

$7.23

0.25 (3.58%)

16:28
11/11/19
11/11
16:28
11/11/19
16:28
Earnings
Apyx Medical reports Q3 EPS (13c), consensus (18c) »

Reports Q3 revenue $7.6M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

  • 12

    Nov

KDMN

Kadmon

$2.99

-0.025 (-0.83%)

16:28
11/11/19
11/11
16:28
11/11/19
16:28
Hot Stocks
Kadmon's KD025 met primary endpoint in interim pivotal trial analysis of KD025 »

Kadmon Holding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVKIF

Evonik

$0.00

(0.00%)

16:27
11/11/19
11/11
16:27
11/11/19
16:27
Upgrade
Evonik rating change  »

Evonik upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.